The estimated Net Worth of Desiree Ralls Morrison is at least $1.56 Миллион dollars as of 11 July 2024. Ms. Morrison owns over 3,489 units of Boston Scientific stock worth over $465,210 and over the last 7 years she sold BSX stock worth over $1,097,067. In addition, she makes $0 as Senior Vice President, General Counsel и Corporate Secretary at Boston Scientific.
Sign up
Ms. Morrison BSX stock SEC Form 4 insiders trading
Desiree has made over 17 trades of the Boston Scientific stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 3,489 units of BSX stock worth $721,002 on 11 July 2024.
The largest trade she's ever made was exercising 12,239 units of Boston Scientific stock on 17 May 2024 worth over $1,015,103. On average, Desiree trades about 2,565 units every 62 days since 2017. As of 11 July 2024 she still owns at least 5,609 units of Boston Scientific stock.
You can see the complete history of Ms. Morrison stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Desiree Ralls-Morrison biography
Desiree Ann Ralls-Morrison J.D. serves as Senior Vice President, General Counsel, Corporate Secretary of the Company. In this role, she is responsible for providing global legal leadership across all of our businesses, regions and functions, and overseeing the company's global compliance function. Before joining Boston Scientific, she was senior vice president, general counsel and corporate secretary, and head of the global litigation, government affairs and public policy organizations, for Boehringer Ingelheim USA, Inc. since October 2013. Prior to that, she spent nine years at Johnson & Johnson, most recently as general counsel for the consumer group, and previously progressed through roles of increasing responsibility, including senior counsel, assistant general counsel, and vice president of law for the women's health, nutritionals and over-the-counter businesses. Earlier in her career, Ms. Ralls-Morrison was a senior attorney and assistant counsel at Merck & Co, Inc., focusing largely on regulatory and product liability matters, and prior to that, she held litigation roles at the law firms of Kelley Drye & Warren LLP and Shipman & Goodwin LLP. She recently served on the Danbury Hospital/New Milford Hospital Board of Directors, The Inner-City Foundation for Charity and Education and the Lawyer's Collaborative for Diversity. Desiree earned her B.A. in economics and political science from Wesleyan University and her J.D. from Harvard Law School.
How old is Desiree Morrison?
Desiree Morrison is 54, she's been the Senior Vice President, General Counsel и Corporate Secretary of Boston Scientific since 2017. There are 20 older and 6 younger executives at Boston Scientific. The oldest executive at Boston Scientific Corp. is Yoshiaki Fujimori, 69, who is the Independent Director.
Insiders trading at Boston Scientific
Over the last 20 years, insiders at Boston Scientific have traded over $938,841,783 worth of Boston Scientific stock and bought 1,398,972 units worth $16,231,539 . The most active insiders traders include Peter M Nicholas, John E Abele и Michael F Mahoney. On average, Boston Scientific executives and independent directors trade stock every 3 days with the average trade being worth of $4,899,929. The most recent stock trade was executed by Michael F Mahoney on 5 September 2024, trading 162,777 units of BSX stock currently worth $13,212,609.
What does Boston Scientific do?
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.
What does Boston Scientific's logo look like?
Complete history of Ms. Morrison stock trades at Boston Scientific, Dicks Sporting Goods и McDonald`s Corp
Boston Scientific executives and stock owners
Boston Scientific executives and other stock owners filed with the SEC include:
-
Michael Mahoney,
Chairman of the Board, President, Chief Executive Officer -
Daniel Brennan,
Chief Financial Officer, Executive Vice President -
Joseph Fitzgerald,
Executive Vice President, President, Interventional Cardiology -
Edward Mackey,
Executive Vice President - Operations -
David Pierce,
Executive Vice President and President, MedSurg and President, Endoscopy -
Michael F. Mahoney,
Chairman, Pres & CEO -
Daniel J. Brennan,
Exec. VP & CFO -
Joseph M. Fitzgerald,
Exec. VP & Pres of Interventional Cardiology -
Edward F. Mackey,
Exec. VP of Global Operations -
Jeffrey B. Mirviss,
Exec. VP & Pres of Peripheral Interventions -
Edward Ludwig,
Lead Independent Director -
Charles Dockendorff,
Independent Director -
David Roux,
Independent Director -
John Sununu,
Independent Director -
Donna James,
Independent Director -
Nelda Connors,
Independent Director -
Ellen Zane,
Independent Director -
Stephen MacMillan,
Independent Director -
Yoshiaki Fujimori,
Independent Director -
John Sorenson,
Senior Vice President - Manufacturing and Supply Chain -
Meghan Scanlon,
Senior Vice President and President, Urology and Pelvic Health -
Scott Olson,
Senior Vice President and President, Rhythm Management -
Maulik Nanavaty,
Senior Vice President and President - Neuromodulation -
Wendy Carruthers,
Senior Vice President - Human Resources -
Desiree Ralls-Morrison,
Senior Vice President, General Counsel, Corporate Secretary -
Jodi Eddy,
Senior Vice President, Chief Information Officer -
Eric Thepaut,
Executive Vice President and President - Europe, Middle East and Africa -
Jeffrey Mirviss,
Executive Vice President and President - Peripheral Interventions -
Ian Meredith,
Executive Vice President, Global Chief Medical Officer -
Arthur Butcher,
Executive Vice President and President, Asia Pacific -
Catherine Jennings,
VP of Global Marketing & New Bus. Devel. of Peripheral Interventions -
Vance R. Brown,
Sr. VP, Gen. Counsel & Corp. Sec. -
Susan Vissers Lisa,
VP of Investor Relations -
Jodi Euerle Eddy,
Sr. VP and Chief Information & Digital Officer -
Jonathan R Monson,
VP, Global Controller & Chief Accounting Officer -
Vance R Brown,
SVP, GC and Corp. Secretary -
Timothy A. Pratt,
EVP & General Counsel -
Supratim Bose,
EVP & President, Asia-Pacific -
Michael P. Phalen,
SVP & President, Endoscopy -
Keith D Dawkins,
Sr. VP, Chief Medical Officer -
Kevin J. Ballinger,
EVP & Pres, Interven Cardio -
Cheryl Pegus,
Director -
David S Wichmann,
Director -
Xin Warren Wang,
SVP and Pres, Asia Pacific -
Peter M Nicholas,
Director -
Kristina M Johnson,
Director -
Nicholas J Jr Nicholas,
Director -
Karen Prange,
SVP&Pres, Uro & Women's Health -
Ernest Mario,
Director -
John E Abele,
Director -
Uwe E Reinhardt,
Director -
Katharine T Bartlett,
Director -
Jean Fitterer Lance,
SVP & Chief Compliance Officer -
Kenneth Pucel,
EVP, Operations -
Bruce L Byrnes,
Director -
John Michael Onuscheck,
SVP & Pres-Neuromodulation -
Jeffrey D Capello,
Chief Accounting Officer -
Otha T. Iii Spriggs,
SVP, Human Resources -
William Kucheman,
SVP & Group President -
John Raymond Elliott,
Director -
Lawrence R Neumann,
SVP and Pres, Emerging Markets -
John B. Pedersen,
Pres,Uro & Women's Health -
Brian R Burns,
SVP - Quality -
Ray J Groves,
Director -
Sam R Leno,
CFO & EVP Finance & IS -
Stephen F Moreci,
Sr. VP, Endosurgery -
Marye Anne Fox,
Director -
Fred Colen,
EVP -
John E Pepper,
Director -
James Gilbert,
EVP -
Donovan Paul,
SVP, Corporate Comm -
David W Mc Faul,
Senior VP International -
Ursula M Burns,
Director -
Warren B Rudman,
Director -
William F Jr Mcconnell,
SVP, Administration CRM -
Donald S Baim,
EVP, Chief Med. & Sci. Officer -
Lucia Luce Quinn,
Exec. Vice President-HR -
James R Tobin,
President & CEO -
Paul W Sandman,
EVP and General Counsel -
Paul A Laviolette,
COO -
Nancy Ann Deparle,
Director -
Joel Lawrence Fleishman,
Director -
David C Habiger,
Director -
Jonathan Monson,
SVP, Global Controller and CAO -
Emily Woodworth,
SVP, Global Controller and CAO -
Jessica L Mega,
Director -
Susan E Morano,
Director